1. Home
  2. IMUX vs ORMP Comparison

IMUX vs ORMP Comparison

Compare IMUX & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.65

Market Cap

200.4M

Sector

Health Care

ML Signal

HOLD

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$4.61

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMUX
ORMP
Founded
2016
2002
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.4M
165.3M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
IMUX
ORMP
Price
$14.65
$4.61
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$36.00
N/A
AVG Volume (30 Days)
195.3K
508.5K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
6.51%
EPS Growth
38.00
412.50
EPS
N/A
0.91
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.05
Revenue Growth
N/A
49.25
52 Week Low
$0.51
$1.98
52 Week High
$15.84
$5.19

Technical Indicators

Market Signals
Indicator
IMUX
ORMP
Relative Strength Index (RSI) 60.42 60.43
Support Level $0.74 $3.69
Resistance Level $15.77 $5.10
Average True Range (ATR) 0.95 0.32
MACD -0.11 0.08
Stochastic Oscillator 66.34 58.74

Price Performance

Historical Comparison
IMUX
ORMP

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Share on Social Networks: